Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Open Access
- 1 July 2005
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (1) , 90-101
- https://doi.org/10.1124/mol.105.011767
Abstract
Upon hormone stimulation, the sst2 somatostatin receptor couples to adenylyl cyclase through Gi/o proteins and undergoes rapid endocytosis via clathrin-coated pits. In this study, we determined the relationship between the ability of ligands to induce sst2 receptor internalization and inhibit adenylyl cyclase. Immunocytochemical studies demonstrated that peptide agonists [such as somatostatin-14, cortistatin-17, octreotide, vapreotide, KE108 (Tyr0-cyclo[d-diaminobutyric acid-Arg-Phe-Phe-d-Trp-Lys-Thr-Phe]), and SOM230 (cyclo[diaminoethylcarbamoyl-hydroxyproline-phenylglycine-d-Trp-Lys-(4-O-benzyl)-l-Tyr-Phe])] and nonpeptide agonists (such as L-779,976), stimulated the rapid endocytosis of sst2 receptors in human embryonic kidney 293 and CHO-K1 cells. In contrast, two antagonists did not induce receptor endocytosis by themselves and completely blocked agonist stimulation. Using a quantitative enzyme-linked immunosorbent assay to measure sst2 receptor sequestration, we found that peptide agonists varied by more than 100-fold in their potencies but exhibited the same efficacy as somatostatin14. In contrast, L-779,976 did not induce maximal receptor internalization. It is interesting that although βarrestin-2 was recruited to cell surface sst2 receptors after stimulation with either somatostatin14 or L-779,976, the βarrestin-receptor complex dissociated earlier in the endocytic pathway with the nonpeptide ligand. Although all agonists, including L-779,976, produced the same maximal inhibition of cyclic AMP, the potency ratio for inhibition of cyclic AMP and stimulation of receptor endocytosis varied by 15-fold. In general, native peptides showed similar potencies for cyclic AMP inhibition and receptor endocytosis, whereas short therapeutic analogs were substantially more potent at inhibiting cyclic AMP synthesis. These results demonstrate that the activity of somatostatin analogs to regulate receptor endocytosis and signaling are not tightly linked and provide compelling evidence for the induction of agonist specific states of the sst2 receptor.Keywords
This publication has 57 references indexed in Scilit:
- Opioid Agonists Have Different Efficacy Profiles for G Protein Activation, Rapid Desensitization, and Endocytosis of Mu-opioid ReceptorsPublished by Elsevier ,2003
- Homologous and Heterologous Regulation of Somatostatin Receptor 2Molecular Endocrinology, 2002
- β‐Arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cellsFEBS Letters, 2002
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Cellular biology of somatostatin receptorsNeuropeptides, 2001
- Endocytosis and recycling of muscarinic receptorsLife Sciences, 1999
- The Endothelin Subtype A Receptor Undergoes Agonist- and Antagonist-Mediated Internalization in the Absence of SignalingEndocrinology, 1998
- A cortical neuropeptide with neuronal depressant and sleep-modulating propertiesNature, 1996
- Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.Proceedings of the National Academy of Sciences, 1986
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982